What Is Hidradenitis Suppurativa? Don’t Ignore Those Lumps


It’s definitely not an easy term to pronounce hidradenitis suppurativa (HS) nor is it an easy condition to live with. Up to four per cent of Canadians are affected by this painful skin disease. However, dermatologist Dr. Afsaneh Alavi, a director of the Wound Healing Fellowship at Women’s College Hospital in Toronto, says diagnosing the condition can often be delayed or is misdiagnosed, making it difficult to adequately assess the true prevalence of the disease.

So, what is hidradenitis suppurativa?

Hidradenitis suppurativa is a long-term skin condition that features small, painful lumps under the skin. Despite also being known as acne inversa, this condition is not a form of acne. The lumps typically develop where the skin rubs together, such as the armpits, the groin, between the buttocks and under the breasts. The lumps may break open and smell or cause tunnels under the skin, according to Dr. Alavi. With time, the lesions can be clustered with residual scarring.

I want young people who have recurrent boils in areas with sweat glands (armpit, groin, buttocks, under breasts, etc), to speak with their doctor right away as there is treatment. I want them to know that it is not their fault, and they shouldn’t blame themselves. HS is not caused by poor hygiene, nor is it a sexually transmitted disease or contagious, it is genetic. Don’t be affected by the stigma. If you have HS, talk about it. There is a lot of support out there.

Watch this teen talk about her experience with hidradenitis suppurativa:

What can hidradenitis suppurativa look and feel like?

Hidradenitis suppurativa often starts with a single, painful bump that persists for weeks or months. For some people, the disease progressively worsens and affects multiple areas of their body. Hidradenitis suppurativa lumps may look like the following:

Blackheads: Small pitted areas of skin containing blackheads — often appearing in pairs.

Red, tender bumps: These bumps often enlarge, break open and drain pus, which can have an odour. The bumps may itch and burn where skin rubs against skin.

Painful, pea-sized lumps: These hard lumps, which develop under the skin, may persist for years, enlarge and become inflamed.

Tunnels: Over time, tracts connecting the lumps may form under the skin. These wounds heal very slowly, if at all, and can leak pus.

Who gets them?

Hidradenitis suppurativa most commonly occurs in women between the ages of 20 and 30. The ratio of female to male is three to one, says Alavi.

The condition can be associated with several other conditions, including arthritis, severe acne, obesity, inflammatory bowel disease, Crohn’s disease, metabolic syndrome and diabetes. And just another reason to ditch the cigarettes: smoking tobacco has been linked to hidradenitis suppurativa.

More from HuffPost Canada:

What causes it?

Dr. Alavi says that while the causes are mostly unknown, it is thought that HS is mainly genetic.

“There is some research that shows HS is a disease of hair follicles that has genetic and environmental causes,” she says. “With heat, the pore can get clogged and a cyst will form, holding a collection of fluid, within a closed area.”

The doctor adds that bacteria then accumulates in this environment and eventually the cyst ruptures and causes inflammation.

“Most of us will get ingrown hair, but people with HS are prone to chronic inflammation and recurring boils, which are painful and cause scarring,” Dr. Alavi told HuffPost Canada.

The doctor says that HS is not caused by poor hygiene, nor is it a sexually transmitted disease or contagious.

When should you go to the doctor?

Patients often suffer for years without effective treatment, leaving them frustrated in addition to helpless and ashamed, said the dermatologist. It is so important that people know about this disease, and to get early medical attention, she adds.

“The average Canadian (HS) patient will see five doctors with over 17 visits spanning eight years before being diagnosed,” says the Canadian Hidradenitis Suppurativa Foundation website.

Early detection is key to getting effective treatment and you should see your doctor if your condition is painful, doesn’t improve in a few weeks, returns within weeks of treatment, appears in several locations and recurs often, according to the Mayo Clinic.

“If diagnosed earlier, treatment can be started right away and potentially lessen the damage that people with this condition often experience,” says Alavi.

If young people notice that they are developing recurrent boils at least twice in a six month period they need to speak to their doctor. Dr. Alavi says that people with HS tend to suffer from the disease for seven to nine years before being diagnosed and “this is unfortunate because of the physical and psychological impact of the disease.”

And, pay attention to any new signs or symptoms as these may indicate either a recurrence or a complication of treatment.

What will a doctor do to treat it?

Depending on the severity of the disease, there are a few different treatment options. As the disease is inflammatory, in most cases patients will need both medical and surgical interventions. Medical interventions can include systemic antibiotics, topical treatments, anti-androgen (hormonal) treatment, and biologic treatment with Adalimumab the only Health Canada-approved medication for the skin disease, says Alavi.

How can you manage it?

Patients play an important role in the management of chronic disease, particularly HS, says Dr. Alavi. They can detect flare-ups and seek treatment right away.

“It is also important that patients recognize triggers that can cause flare-ups, such as wearing tight clothing, shaving, smoking and gaining weight,” she says.

It has been shown that smoking and obesity play a role in flare ups of the disease. Some patients also find that removing dairy from their diet helps, but there is no research to support this.

There’s no cure for HS, so you’ll have to manage the condition for life.

Also on HuffPost: How to prevent in-grown hairs.





Source link

ChemoCentryx (CCXI) versus Stellar Biotechnologies (SBOT) Financial Contrast


ChemoCentryx (NASDAQ: CCXI) and Stellar Biotechnologies (NASDAQ:SBOT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for ChemoCentryx and Stellar Biotechnologies, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ChemoCentryx 0 1 3 1 3.00
Stellar Biotechnologies 0 0 0 0 N/A

ChemoCentryx presently has a consensus price target of $17.75, indicating a potential upside of 56.11%. Given ChemoCentryx’s higher probable upside, equities analysts plainly believe ChemoCentryx is more favorable than Stellar Biotechnologies.

Valuation and Earnings

This table compares ChemoCentryx and Stellar Biotechnologies’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ChemoCentryx $82.50 million 6.77 $17.69 million $0.36 31.58
Stellar Biotechnologies $230,000.00 22.17 -$5.03 million ($3.43) -0.45

ChemoCentryx has higher revenue and earnings than Stellar Biotechnologies. Stellar Biotechnologies is trading at a lower price-to-earnings ratio than ChemoCentryx, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

50.3% of ChemoCentryx shares are owned by institutional investors. Comparatively, 6.9% of Stellar Biotechnologies shares are owned by institutional investors. 14.5% of ChemoCentryx shares are owned by insiders. Comparatively, 7.8% of Stellar Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

ChemoCentryx has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Stellar Biotechnologies has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500.

Profitability

This table compares ChemoCentryx and Stellar Biotechnologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ChemoCentryx N/A 31.56% 9.03%
Stellar Biotechnologies -4,766.06% -77.77% -72.53%

Summary

ChemoCentryx beats Stellar Biotechnologies on 13 of the 14 factors compared between the two stocks.

ChemoCentryx Company Profile

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.

Stellar Biotechnologies Company Profile

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company’s products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.

Receive News & Ratings for ChemoCentryx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ChemoCentryx and related companies with MarketBeat.com’s FREE daily email newsletter.





Source link

European Medicines Agency's CHMP Says Yes To 7 Drugs, No To 1



… Psoriasis, Hidradenitis suppurativa, Crohn's disease, Ulcerative colitis and Uveitis in adults, and for the treatment of pediatric inflammatory diseases, …



Source link

Hidradenitis Suppurativa Market Analysed the World’s Main Region Market Conditions, Including Product Price, Profit by 2022


Hidradenitis Suppurativa Market report focuses on growth analysis and historical & futuristic cost of Hidradenitis Suppurativa industry. Hidradenitis Suppurativa Market research report provides granular analysis of the Competitive Situation and Trends, Production, Average Price, Manufacturing Base Distribution, Sales Area and Product by Types, Concentration Rate, Mergers & Acquisitions, Expansion, Revenue and Share by Manufacturers.

Get Sample PDF of a report at https://www.absolutereports.com/enquiry/request-sample/12396319     

The Report Comprises of Various Company Profiles of Fundamental Market Players of Hidradenitis Suppurativa Market

With thorough market segment in terms of different Countries, this report divides the market into a few key countries, with sales (consumption), revenue, market share, and growth rate of the market in these countries over the forecast period 2022.

Browse Detailed TOC, Tables, Figures, Charts and Companies Mentioned in Hidradenitis Suppurativa Market Research Report at – https://www.absolutereports.com/12396319

The Hidradenitis Suppurativa Market to grow at a substantial Compound Annual Growth Rate during the forecast period 2022.

 Geographical Segmentation of Hidradenitis Suppurativa Market:

  • North America
  • Europe
  • Asia-Pacific (APAC)
  • Middle East and Africa
  • Rest of World (ROW)

The research report offers answers to several important questions related to the growth of the Hidradenitis Suppurativa market. Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered. In a word, the report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. 

Have any query? Ask our Experts athttps://www.absolutereports.com/enquiry/pre-order-enquiry/12396319        

Major Table of Contents of Mentioned in the Report 2022

  • Hidradenitis Suppurativa Market Overview (2022)
    • Product Overview and Scope
    • Market Segment by by Types
    • Production Market Share
    • Hidradenitis Suppurativa Consumption Market Share by Application
    • Market Size (Value) and Applications
    • Hidradenitis Suppurativa Status and Outlook
    • Government Policies
  • Hidradenitis Suppurativa Market Competition by Manufacturers (2022)
    • Hidradenitis Suppurativa Market by Capacity, Production and Share by Manufacturers
    • Revenue and Share by Manufacturers
    • Average Price by Manufacturers By Market
    • Manufacturers Manufacturing Base Distribution, Sales Area, Product by Types
    • Market Competitive Situation and Trends
    • Market Concentration Rate
    • Hidradenitis Suppurativa Market Share of Top 3 and Top 5 Manufacturers
  • Hidradenitis Suppurativa Market Manufacturers Profiles/Analysis (2022)
    • Company Name
    • Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    • Hidradenitis Suppurativa Market by Product by Types, Application and Specification
    • Company A Hidradenitis Suppurativa Capacity, Production, Revenue, Price and Gross Margin
    • Main Business/Business Overview
  • Hidradenitis Suppurativa Market Capacity, Production, Revenue, Consumption, Export and Import (2022)
    • Market Capacity, Production and Growth
    • Revenue and Growth of Market
    • Production, Consumption, Export and Import
  • Hidradenitis Suppurativa Market Production, Revenue (Value), Price Trend by by Types (2022)
    • Hidradenitis Suppurativa Market by Production and Market Share by by Types
    • Revenue and Market Share by by Types
    • Price by by Types
    • Production Growth by by Types
  • Hidradenitis Suppurativa Market Analysis by Application (2022)
    • Hidradenitis Suppurativa Market Consumption and Market Share by Application
    • Consumption Growth Rate by Application
    • Market Drivers and Opportunities
    • Potential Application
    • Emerging Markets/Countries

……And Many more.

Price of Report: $ 2850 (Single User Licence)

Purchase Hidradenitis Suppurativa Market Report at https://www.absolutereports.com/purchase/12396319          

The Hidradenitis Suppurativa market report highlight the economy, past and emerging trend of industry, and availability of basic resources. Furthermore, the market report explains development trend, analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Hidradenitis Suppurativa market before evaluating its possibility.


Post Views:
6



Source link

ChemoCentryx, Inc. (CCXI) EPS Estimated At $-0.11; Sabre Industries (SABR) Has 1.76 Sentiment




July 30, 2018 – By Vernon Prom

Sabre Corporation (NASDAQ:SABR) Logo

Sabre Industries Inc (SABR) investors sentiment increased to 1.76 in Q1 2018. It’s up 0.29, from 1.47 in 2017Q4. The ratio is positive, as 167 funds increased or started new positions, while 95 reduced and sold their stakes in Sabre Industries Inc. The funds in our database reported: 289.05 million shares, down from 294.44 million shares in 2017Q4. Also, the number of funds holding Sabre Industries Inc in top ten positions increased from 3 to 5 for an increase of 2. Sold All: 19 Reduced: 76 Increased: 105 New Position: 62.

Analysts expect ChemoCentryx, Inc. (NASDAQ:CCXI) to report $-0.11 EPS on August, 14.They anticipate $0.08 EPS change or 42.11% from last quarter’s $-0.19 EPS. After having $-0.19 EPS previously, ChemoCentryx, Inc.’s analysts see -42.11% EPS growth. The stock decreased 0.53% or $0.06 during the last trading session, reaching $11.31. About 74,188 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 83.50% since July 30, 2017 and is uptrending. It has outperformed by 70.93% the S&P500. Some Historical CCXI News: 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx

Silver Lake Group L.L.C. holds 13.27% of its portfolio in Sabre Corporation for 22.47 million shares. Tpg Group Holdings (Sbs) Advisors Inc. owns 36.99 million shares or 11.95% of their US portfolio. Moreover, Praesidium Investment Management Company Llc has 5.11% invested in the company for 2.90 million shares. The New York-based Md Sass Investors Services Inc has invested 4.17% in the stock. Burgundy Asset Management Ltd., a Ontario – Canada-based fund reported 18.12 million shares.

Sabre Corporation, through its subsidiary, Sabre Holdings Corporation, provides technology solutions to the travel and tourism industry worldwide. The company has market cap of $7.12 billion. It operates through two divisions, Travel Network, and Airline and Hospitality Solutions. It has a 29.68 P/E ratio. The Travel Network segment operates as a business-to-business travel marketplace that offers travel content, such as inventory, prices, and availability from a range of travel suppliers, including airlines, hotels, car rental brands, rail carriers, cruise lines, and tour operators with a network of travel buyers comprising online and offline travel agencies, travel management companies, and corporate travel departments.

Analysts await Sabre Corporation (NASDAQ:SABR) to report earnings on July, 31 before the open. They expect $0.31 earnings per share, down 3.13% or $0.01 from last year’s $0.32 per share. SABR’s profit will be $85.18M for 20.90 P/E if the $0.31 EPS becomes a reality. After $0.39 actual earnings per share reported by Sabre Corporation for the previous quarter, Wall Street now forecasts -20.51% negative EPS growth.

The stock increased 0.39% or $0.1 during the last trading session, reaching $25.91. About 1.03 million shares traded. Sabre Corporation (SABR) has risen 4.27% since July 30, 2017 and is uptrending. It has underperformed by 8.30% the S&P500. Some Historical SABR News: 24/05/2018 – Ketchum Wins Seven EMEA SABRE Awards; 23/05/2018 – S&PGR: Expect Sabre Will Maintain Leadership Position in Global Travel Distribution Systems Business and Grow Airlines Solution and Hospitality Business; 22/03/2018 – SABRE INSURANCE GROUP PLC SBRE.L – FY COMBINED OPERATING RATIO 68.5% VS 69.3%; 01/05/2018 – Alaska Airlines Migrates Virgin Amer Into Their Sabre Passenger Services System; 22/03/2018 – SABRE INSURANCE GROUP PLC SBRE.L – FY SOLVENCY COVERAGE RATIO 160% VS 128%; 14/05/2018 – Laurion Capital Buys New 1% Position in Sabre; 30/05/2018 – Sabre Insurance Cofounder, Investor Sell 18% Stake for GBP112.8 Mln; 23/05/2018 – S&P REVISES SABRE HOLDINGS CORP. TO RATING ‘BB’ FROM ‘BB-‘; 23/05/2018 – S&P REVISES SABRE CORP. TO RATING ‘BB’ FROM ‘BB-‘; 22/05/2018 – LATAM Airlines Group now fully powered by Sabre’s passenger services system

Another recent and important Sabre Corporation (NASDAQ:SABR) news was published by Seekingalpha.com which published an article titled: “Aerolineas Argentinas renews partnership with Sabre” on July 12, 2018.

Investors sentiment decreased to 1 in Q1 2018. Its down 0.30, from 1.3 in 2017Q4. It is negative, as 10 investors sold ChemoCentryx, Inc. shares while 36 reduced holdings. 24 funds opened positions while 22 raised stakes. 24.22 million shares or 3.03% more from 23.51 million shares in 2017Q4 were reported. National Bank Of Ny Mellon Corporation accumulated 106,620 shares. Moreover, Arrowstreet Partnership has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Bb&T Secs Ltd Co holds 83,500 shares. Ameritas Inv Prns reported 2,120 shares. Fernwood Invest Ltd Liability Company invested 0.08% in ChemoCentryx, Inc. (NASDAQ:CCXI). The Pennsylvania-based Pnc Fin Grp Inc has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Renaissance Lc reported 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI). Fny Managed Accounts Lc stated it has 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). 11,574 are held by Trexquant Limited Partnership. Barclays Public Limited Company stated it has 13,066 shares or 0% of all its holdings. Clarivest Asset Mngmt stated it has 79,000 shares or 0.02% of all its holdings. Schwab Charles Inv Inc reported 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Royal Natl Bank Of Canada invested in 0% or 3 shares. California State Teachers Retirement Sys accumulated 0% or 38,188 shares. The New York-based Jane Street Grp Ltd Llc has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI).

Since May 1, 2018, it had 0 insider purchases, and 12 insider sales for $7.89 million activity. Schall Thomas J. sold $2.36M worth of stock or 200,000 shares. KANAYA SUSAN M sold $752,925 worth of stock. $590,637 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) was sold by Cappel Markus J..

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $555.89 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 39 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe Crohn’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 4 analyst reports since March 13, 2018 according to SRatingsIntel. The rating was maintained by JP Morgan on Tuesday, March 13 with “Overweight”.

Sabre Corporation (NASDAQ:SABR) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.




Source link

$-0.40 EPS Expected for InflaRx N.V. (IFRX); Ternium S.A. (TX) Covered By 2 Bullish Analysts Last Week




July 30, 2018 – By Ashley Bratcher

Ternium S.A. (NYSE:TX) Logo

Among 2 analysts covering Ternium SA (NYSE:TX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ternium SA had 3 analyst reports since February 8, 2018 according to SRatingsIntel. As per Thursday, February 8, the company rating was maintained by Scotia Capital. Scotia Capital maintained Ternium S.A. (NYSE:TX) rating on Thursday, April 19. Scotia Capital has “Buy” rating and $4700 target. Credit Suisse upgraded the shares of TX in report on Tuesday, May 15 to “Outperform” rating. See Ternium S.A. (NYSE:TX) latest ratings:

15/05/2018 Broker: Credit Suisse Old Rating: Neutral New Rating: Outperform Upgrade
19/04/2018 Broker: Scotia Capital Rating: Buy New Target: $47.0000 Maintain
08/02/2018 Broker: Scotia Capital Rating: Buy New Target: $43.0 Maintain

Analysts expect InflaRx N.V. (NASDAQ:IFRX) to report $-0.40 EPS on August, 16.After having $-0.49 EPS previously, InflaRx N.V.’s analysts see -18.37% EPS growth. The stock decreased 0.69% or $0.21 during the last trading session, reaching $30.44. About 3,421 shares traded. InflaRx N.V. (NASDAQ:IFRX) has 0.00% since July 30, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical IFRX News: 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. The company has market cap of $781.15 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Seekingalpha.com which released: “Biotech: Take It On The Run” on July 05, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on July 13, 2018, Schaeffersresearch.com published: “3 Healthcare Stocks Making Massive Moves” on July 13, 2018. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Streetinsider.com and their article: “BMO Capital Starts Inflarx NV (IFRX) at Outperform” published on July 13, 2018 as well as Benzinga.com‘s news article titled: “30 Stocks Moving In Friday’s Mid-Day Session” with publication date: July 13, 2018.

More news for Ternium S.A. (NYSE:TX) were recently published by: Seekingalpha.com, which released: “Nucor: Leveraging Higher Prices And Prior Growth Investments” on July 26, 2018. Nasdaq.com‘s article titled: “5 New Strong Buy Stocks for July 16th” and published on July 16, 2018 is yet another important article.

Ternium S.A. manufactures and processes various steel products in Mexico, Argentina, Bolivia, Chile, Paraguay, Uruguay, Colombia, the United States, Central America, and internationally. The company has market cap of $7.16 billion. The firm operates in two divisions, Steel and Mining. It has a 7.22 P/E ratio. The Steel segment offers steel products, such as slabs, billets and round bars, hot-rolled coils and sheets, bars and stirrups, wire rods, cold-rolled coils and sheets, tin plates, hot dipped galvanized and electrogalvanized sheets, pre-painted sheets, steel pipes and tubular products, beams, roll formed products, and other products.

The stock increased 0.03% or $0.01 during the last trading session, reaching $36.47. About 227,175 shares traded. Ternium S.A. (NYSE:TX) has risen 46.05% since July 30, 2017 and is uptrending. It has outperformed by 33.48% the S&P500. Some Historical TX News: 25/04/2018 – Ternium 1Q EPS $1.87; 24/04/2018 – Ternium Files 2017 Form 20-F; 15/05/2018 – TERNIUM SA TX.N : CREDIT SUISSE RAISES TARGET PRICE TO $50 FROM $35.80; 02/05/2018 – Shareholders Approve All Resolutions on Agenda of Ternium’s Annual and Extraordinary General Meetings; 25/04/2018 – Ternium Expects Operating Income to Increase in 2Q Versus 1Q; 25/04/2018 – Ternium 1Q Operating Income Was $523.1 Million; 21/03/2018 Ternium Announces Annual and Extraordinary General Meetings of Shareholders; 25/04/2018 – TERNIUM SA QTRLY EARNINGS PER ADS $1.87; 10/04/2018 – Brazil steelmaker Usiminas says shareholders reach agreement; 11/04/2018 – Consolidated Research: 2018 Summary Expectations for Ternium S.A, CNB Financial, Barrick Gold, New York Mortgage Trust, Ascendi

Ternium S.A. (NYSE:TX) Ratings Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

Chemocentryx (CCXI) Valuation Rose While Bvf Has Cut Position by $5.02 Million; Fiserv (FISV) Shareholder Headinvest Has Raised Its Holding by $3.42 Million as Share Value Declined




July 30, 2018 – By Jason Dias

Fiserv, Inc. (NASDAQ:FISV) Logo

Headinvest Llc increased its stake in Fiserv (FISV) by 94.67% based on its latest 2018Q1 regulatory filing with the SEC. Headinvest Llc bought 48,172 shares as the company’s stock declined 1.25% with the market. The institutional investor held 99,054 shares of the technology company at the end of 2018Q1, valued at $7.06 million, up from 50,882 at the end of the previous reported quarter. Headinvest Llc who had been investing in Fiserv for a number of months, seems to be bullish on the $30.52 billion market cap company. The stock decreased 2.06% or $1.57 during the last trading session, reaching $74.55. About 1.02M shares traded. Fiserv, Inc. (NASDAQ:FISV) has risen 15.27% since July 30, 2017 and is uptrending. It has outperformed by 2.70% the S&P500.

Bvf Inc decreased its stake in Chemocentryx Inc (CCXI) by 5.09% based on its latest 2018Q1 regulatory filing with the SEC. Bvf Inc sold 386,100 shares as the company’s stock rose 32.26% while stock markets declined. The hedge fund held 7.20M shares of the health care company at the end of 2018Q1, valued at $97.94M, down from 7.59 million at the end of the previous reported quarter. Bvf Inc who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $551.96M market cap company. The stock decreased 1.23% or $0.14 during the last trading session, reaching $11.23. About 106,849 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 83.50% since July 30, 2017 and is uptrending. It has outperformed by 70.93% the S&P500. Some Historical CCXI News: 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting

Among 24 analysts covering Fiserv (NASDAQ:FISV), 10 have Buy rating, 1 Sell and 13 Hold. Therefore 42% are positive. Fiserv had 61 analyst reports since July 30, 2015 according to SRatingsIntel. BMO Capital Markets maintained Fiserv, Inc. (NASDAQ:FISV) rating on Thursday, February 8. BMO Capital Markets has “Market Perform” rating and $152 target. The firm has “Neutral” rating by Citigroup given on Wednesday, May 2. Stephens maintained Fiserv, Inc. (NASDAQ:FISV) on Monday, February 5 with “Hold” rating. The rating was upgraded by Argus Research on Monday, May 9 to “Buy”. The firm has “Sell” rating by Compass Point given on Friday, April 15. The stock has “Neutral” rating by Credit Suisse on Wednesday, May 2. The stock of Fiserv, Inc. (NASDAQ:FISV) has “Buy” rating given on Wednesday, October 11 by Jefferies. The firm has “Hold” rating by SunTrust given on Tuesday, October 31. The firm earned “Equal Weight” rating on Thursday, July 30 by Barclays Capital. Robert W. Baird maintained Fiserv, Inc. (NASDAQ:FISV) on Wednesday, September 6 with “Buy” rating.

Since February 16, 2018, it had 1 buy, and 7 selling transactions for $19.83 million activity. DiSimone Harry had bought 353 shares worth $49,981. The insider ROBAK KIM M sold 10,388 shares worth $757,493. 50,000 shares were sold by YABUKI JEFFERY W, worth $3.85M.

Investors sentiment increased to 10.53 in Q1 2018. Its up 9.72, from 0.81 in 2017Q4. It is positive, as 39 investors sold FISV shares while 21 reduced holdings. 70 funds opened positions while 562 raised stakes. 700.79 million shares or 293.94% more from 177.89 million shares in 2017Q4 were reported. Los Angeles Cap Mngmt & Equity Research Inc has 221,416 shares for 0.09% of their portfolio. Exxonmobil Invest Tx invested in 0.13% or 63,260 shares. Morgan Stanley has invested 0.02% in Fiserv, Inc. (NASDAQ:FISV). Moreover, San Francisco Sentry Investment Group (Ca) has 0.01% invested in Fiserv, Inc. (NASDAQ:FISV) for 424 shares. National Bank Of Montreal Can holds 746,738 shares. Sva Plumb Wealth Management Ltd Llc, a Wisconsin-based fund reported 54,480 shares. Montag A & Associates owns 127,152 shares for 0.93% of their portfolio. Thompson Siegel Walmsley Lc has 1,896 shares. Cibc Asset Mngmt owns 183,662 shares. Louisiana State Employees Retirement reported 25,200 shares. Bailard Incorporated holds 0.1% or 21,200 shares in its portfolio. Moreover, Cullinan Assoc has 0.38% invested in Fiserv, Inc. (NASDAQ:FISV). Homrich Berg owns 0.03% invested in Fiserv, Inc. (NASDAQ:FISV) for 6,492 shares. Addenda owns 20,438 shares. New York State Common Retirement Fund accumulated 1.11M shares or 0.1% of the stock.

Investors sentiment decreased to 1 in Q1 2018. Its down 0.30, from 1.3 in 2017Q4. It is negative, as 10 investors sold CCXI shares while 36 reduced holdings. 24 funds opened positions while 22 raised stakes. 24.22 million shares or 3.03% more from 23.51 million shares in 2017Q4 were reported. Td Asset Mngmt has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Credit Suisse Ag has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Bogle Invest Management Lp De reported 21,104 shares. Smith Asset Management Group Lp holds 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 26,447 shares. New York State Common Retirement Fund, a New York-based fund reported 37,100 shares. Moreover, Franklin Res has 0.01% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Clarivest Asset Management Limited Co invested in 0.02% or 79,000 shares. Nantahala Capital Management Limited Liability Co owns 600,488 shares. Element Cap Ltd Liability Corp, New York-based fund reported 14,453 shares. Millennium Management Limited Liability invested 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI). 259,558 are owned by Geode Mgmt Ltd Com. Panagora Asset Mngmt holds 0.02% or 369,959 shares. Citadel Advsrs Limited has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Alliancebernstein Ltd Partnership reported 40,100 shares stake. Strs Ohio accumulated 55,500 shares.

Among 7 analysts covering ChemoCentryx (NASDAQ:CCXI), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. ChemoCentryx had 9 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was downgraded by Zacks to “Sell” on Thursday, September 3. Cowen & Co maintained ChemoCentryx, Inc. (NASDAQ:CCXI) on Tuesday, August 8 with “Hold” rating. The firm has “Buy” rating given on Thursday, August 10 by JMP Securities. The stock has “Sell” rating by Zacks on Monday, September 21. The firm earned “Overweight” rating on Tuesday, March 13 by JP Morgan. JMP Securities initiated the stock with “Mkt Outperform” rating in Tuesday, February 21 report.

Since May 1, 2018, it had 0 insider purchases, and 12 sales for $7.89 million activity. Schall Thomas J. had sold 50,000 shares worth $550,858 on Tuesday, May 1. On Wednesday, May 2 KANAYA SUSAN M sold $15,709 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) or 1,366 shares.

Bvf Inc, which manages about $999.89 million and $986.48 million US Long portfolio, upped its stake in Corvus Pharmaceuticals Inc by 1.49M shares to 1.95M shares, valued at $22.53 million in 2018Q1, according to the filing. It also increased its holding in Pieris Pharmaceuticals Inc by 968,987 shares in the quarter, for a total of 3.59M shares, and has risen its stake in Verastem Inc (NASDAQ:VSTM).

Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on August, 14. They expect $-0.11 EPS, up 42.11% or $0.08 from last year’s $-0.19 per share. After $-0.19 actual EPS reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts -42.11% EPS growth.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.




Source link

Unitedhealth Group (UNH) Shareholder Morgens Waterfall Vintiadis & Co Cut Its Holding; Chemocentryx (CCXI) Holder Baker Bros Advisors LP Has Lifted Its Holding by $4.74 Million




July 29, 2018 – By Margaret Staats

UnitedHealth Group Incorporated (NYSE:UNH) Logo

Baker Bros Advisors Lp increased its stake in Chemocentryx Inc. (CCXI) by 743.85% based on its latest 2018Q1 regulatory filing with the SEC. Baker Bros Advisors Lp bought 364,965 shares as the company’s stock rose 32.26% while stock markets declined. The hedge fund held 414,029 shares of the health care company at the end of 2018Q1, valued at $5.63M, up from 49,064 at the end of the previous reported quarter. Baker Bros Advisors Lp who had been investing in Chemocentryx Inc. for a number of months, seems to be bullish on the $558.84 million market cap company. The stock decreased 8.53% or $1.06 during the last trading session, reaching $11.37. About 162,714 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 83.50% since July 29, 2017 and is uptrending. It has outperformed by 70.93% the S&P500. Some Historical CCXI News: 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx

Morgens Waterfall Vintiadis & Co Inc decreased its stake in Unitedhealth Group Inc (UNH) by 28.17% based on its latest 2018Q1 regulatory filing with the SEC. Morgens Waterfall Vintiadis & Co Inc sold 4,200 shares as the company’s stock rose 4.65% while stock markets declined. The hedge fund held 10,712 shares of the medical specialities company at the end of 2018Q1, valued at $2.29M, down from 14,912 at the end of the previous reported quarter. Morgens Waterfall Vintiadis & Co Inc who had been investing in Unitedhealth Group Inc for a number of months, seems to be less bullish one the $245.96B market cap company. The stock decreased 0.41% or $1.05 during the last trading session, reaching $255.95. About 1.66M shares traded. UnitedHealth Group Incorporated (NYSE:UNH) has risen 37.57% since July 29, 2017 and is uptrending. It has outperformed by 25.00% the S&P500. Some Historical UNH News: 17/04/2018 – UnitedHealth 1Q Net $2.84B; 04/04/2018 – UnitedHealthcare Launches Step Up for Better Health Sweepstakes with GHR to Encourage Walking and Support Boys & Girls Clubs; 14/03/2018 – Zachary Tracer: SCOOP: UnitedHealth is no longer interested in a deal for Envision or its surgery centers. Comes after Envision; 13/03/2018 – UNITEDHEALTH GROUP INC – WITTY WILL STEP DOWN FROM UNITEDHEALTH GROUP BOARD OF DIRECTORS, EFFECTIVE IMMEDIATELY; 11/05/2018 – MOODY’S ASSIGNS BAA3 RATINGS TO DAVITA’S SENIOR SECURED TERM LOAN ADD-ONS; 02/04/2018 – Humana, MultiPlan, Optum, Quest, UnitedHealth Launch Blockchain Pilot Program; 24/05/2018 – UnitedHealth: LabCorp to Continue as UnitedHealth’s Exclusive National Laboratory Provider Until Jan. 1, 2019; 29/05/2018 – Molina Healthcare Elects Richard Zoretic to Board of Directors; 11/04/2018 – Online therapy start-up Talkspace hires a chief medical officer from UnitedHealth; 12/04/2018 – Former UnitedHealth Group Executives Join Talkspace – Neil Leibowitz, MD, JD as Chief Medical Officer; Deb Adler as Senior VP, Network and Quality

Among 7 analysts covering ChemoCentryx (NASDAQ:CCXI), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. ChemoCentryx had 9 analyst reports since September 3, 2015 according to SRatingsIntel. On Tuesday, March 13 the stock rating was maintained by JP Morgan with “Overweight”. On Tuesday, August 8 the stock rating was maintained by Cowen & Co with “Hold”. Zacks downgraded the stock to “Sell” rating in Monday, September 21 report. JMP Securities initiated ChemoCentryx, Inc. (NASDAQ:CCXI) on Tuesday, February 21 with “Mkt Outperform” rating. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) has “Buy” rating given on Thursday, August 10 by JMP Securities. The firm has “Sell” rating by Zacks given on Thursday, September 3.

Baker Bros Advisors Lp, which manages about $8.20B and $11.80B US Long portfolio, decreased its stake in Ablynx Nv by 1.98 million shares to 2.18M shares, valued at $118.77M in 2018Q1, according to the filing. It also reduced its holding in Ovid Therapeutics Inc. by 85,600 shares in the quarter, leaving it with 247,733 shares, and cut its stake in Progenics Pharmaceuticals Inc. (NASDAQ:PGNX).

Since May 1, 2018, it had 0 buys, and 12 sales for $7.89 million activity. Another trade for 100 shares valued at $1,410 was sold by KANAYA SUSAN M. Another trade for 10,857 shares valued at $152,028 was made by Schall Thomas J. on Thursday, June 28.

Investors sentiment decreased to 1 in Q1 2018. Its down 0.30, from 1.3 in 2017Q4. It turned negative, as 10 investors sold CCXI shares while 36 reduced holdings. 24 funds opened positions while 22 raised stakes. 24.22 million shares or 3.03% more from 23.51 million shares in 2017Q4 were reported. Prelude Cap Management Ltd Liability Corporation owns 983 shares. 45,740 are held by Keybank Association Oh. Connor Clark Lunn Invest Management reported 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Arrowstreet Limited Partnership holds 0% or 34,216 shares. Renaissance Tech Ltd Liability Corporation stated it has 0.01% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). State Of Wisconsin Invest Board reported 19,000 shares. Td Asset Mgmt has 20,300 shares for 0% of their portfolio. Carmignac Gestion invested in 0.04% or 390,097 shares. National Bank Of America De invested in 85,137 shares. Rhumbline Advisers holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 23,578 shares. Tiaa Cref Invest Mgmt invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Legal & General Gru Pcl stated it has 4,583 shares. Employees Retirement Systems Of Ohio owns 117,524 shares or 0.01% of their US portfolio. Jane Street Gru Lc holds 0% or 14,429 shares in its portfolio. Acadian Asset Ltd Llc owns 521,864 shares for 0.03% of their portfolio.

Morgens Waterfall Vintiadis & Co Inc, which manages about $187.68 million and $131.52M US Long portfolio, upped its stake in On Semiconductor Corp (ONNN) by 54,770 shares to 149,770 shares, valued at $3.66M in 2018Q1, according to the filing. It also increased its holding in Royal Dutch Shell Plc by 12,500 shares in the quarter, for a total of 20,292 shares, and has risen its stake in Editas Medicine Inc.

More notable recent UnitedHealth Group Incorporated (NYSE:UNH) news were published by: Fool.com which released: “Why Omnicom, UnitedHealth Group, and Goldman Sachs Slumped Today” on July 17, 2018, also Fool.com with their article: “Here’s What UnitedHealth Investors Should Be Watching” published on July 19, 2018, Nasdaq.com published: “Lyfebulb and UnitedHealth Group Announce Winners of the 2018 Innovation Challenge for Patient Entrepreneurs” on July 26, 2018. More interesting news about UnitedHealth Group Incorporated (NYSE:UNH) were released by: Bizjournals.com and their article: “UnitedHealth may bid for Tenet health-management unit; deal could fetch $2B” published on July 19, 2018 as well as 247Wallst.com‘s news article titled: “Microsoft Adds to Lead as Dow’s Top-Performing Stock” with publication date: July 28, 2018.

Since January 31, 2018, it had 0 insider buys, and 11 insider sales for $28.49 million activity. Another trade for 202 shares valued at $47,959 was made by Shine Kenneth Irwin on Thursday, April 19. 22,184 shares were sold by RENFRO LARRY C, worth $5.08M. $2.38M worth of stock was sold by HOOPER MICHELE J on Wednesday, January 31. WILENSKY GAIL R sold $779,001 worth of stock or 3,090 shares. $3.28M worth of stock was sold by Nelson Steven H on Thursday, March 15.

Among 27 analysts covering UnitedHealth Group (NYSE:UNH), 26 have Buy rating, 0 Sell and 1 Hold. Therefore 96% are positive. UnitedHealth Group had 94 analyst reports since September 2, 2015 according to SRatingsIntel. Deutsche Bank maintained the shares of UNH in report on Thursday, July 13 with “Buy” rating. The company was downgraded on Monday, June 11 by Credit Suisse. The stock of UnitedHealth Group Incorporated (NYSE:UNH) earned “Overweight” rating by Morgan Stanley on Wednesday, June 7. Piper Jaffray initiated the stock with “Overweight” rating in Wednesday, January 4 report. Jefferies maintained it with “Buy” rating and $280.0 target in Friday, January 12 report. The firm has “Buy” rating by Bernstein given on Wednesday, April 18. Cantor Fitzgerald maintained the shares of UNH in report on Wednesday, June 7 with “Buy” rating. Stifel Nicolaus maintained the stock with “Buy” rating in Tuesday, June 27 report. The company was maintained on Thursday, August 17 by Morgan Stanley. Mizuho maintained it with “Buy” rating and $20000 target in Tuesday, July 18 report.

Analysts await UnitedHealth Group Incorporated (NYSE:UNH) to report earnings on October, 16. They expect $3.30 earnings per share, up 24.06% or $0.64 from last year’s $2.66 per share. UNH’s profit will be $3.17B for 19.39 P/E if the $3.30 EPS becomes a reality. After $3.14 actual earnings per share reported by UnitedHealth Group Incorporated for the previous quarter, Wall Street now forecasts 5.10% EPS growth.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link